Age

18–90

Sex

MALE

Healthy volunteers

Not accepted

suspected prostate cancer warranting standard of care multi-core prostate biopsy

Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature
Patients with a creatinine clearance cutoﬀ (CrCl) of \< 60 mL/min

A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS